KMS Pharma delivers contract analytical testing and method development designed to verify drug substance purity, evaluate formulation stability, investigate process-related degradation products, and compile defensible Module 3 CTD sections.
When partnering with a pharmaceutical analytical development company in India, technical directors and quality leaders require methods that are not only fit-for-purpose on the bench, but rugged enough to transfer seamlessly to commercial manufacturing facilities and external contract testing laboratories without chromatographic drift, baseline noise, or repeatability failures.
Independent Pharmaceutical Analytical Development Company in India
Analytical development defines the quality specifications, testing protocols, and release criteria of modern pharmaceutical products. From active pharmaceutical ingredient (API) identification and assay quantification to trace-level nitrosamine detection and polymorph stability, accurate analytical measurement underpins every milestone in the drug development pipeline.
KMS Pharma provides systematic analytical support bridging early chemical synthesis, preformulation trials, pilot-scale exhibit runs, and post-commercial lifecycle changes. Working in synergy with formulation development teams, our analysts design methods optimized around specific therapeutic delivery systems—including solid orals, lyophilised cakes, sterile solutions, and complex topical matrices.
Method development and validation represent distinct yet intertwined stages of the analytical lifecycle. Development focuses on column selection, mobile phase optimization, extraction recovery, and chromatographic resolution. Validation then evaluates performance against predetermined acceptance criteria according to ICH Q2(R2) and pharmacopeial monographs.
Analytical Method Development
Developing robust, stability-indicating HPLC, GC, and LC-MS/MS methods designed around the drug substance, degradation pathways, and intended matrix.
ICH Q2(R2) Method Validation
Systematic verification of specificity, linearity, precision, intermediate precision, accuracy, limit of detection (LOD), limit of quantitation (LOQ), and robustness.
20+ Years R&D Experience
Deep domain capability solving complex peak co-elution challenges, matrix interferences, and analytical method transfers across global CDMO sites.
Reliable analytical development is not simply about producing test numbers. It is about establishing scientific methods that produce dependable, defensible data under rigorous regulatory audits.
Contract Pharmaceutical Testing & Analytical R&D Services
Pharmaceutical sponsors, virtual biotech companies, and generic manufacturers frequently turn to specialised contract analytical laboratories in India to handle specialized testing, deconvolute difficult formulation matrices, and accelerate registration timelines.
KMS Pharma operates as a dedicated technical partner, supporting project teams from exploratory bench work through to formal stability reports and submission-ready analytical documentation.
Compendial & Non-Compendial Testing
Full monograph characterisation under IP, USP, BP, and Ph. Eur., including assay, related substances, heavy metals, and residual solvents.
Preformulation Characterisation
Evaluating solid-state characteristics, thermal profiles (DSC/TGA), intrinsic dissolution rates, and drug-excipient compatibility under stress conditions.
Finished Dosage Form Testing
Batch release testing, assay uniformity, content uniformity, blend uniformity verification, and degradation product tracking for solid and liquid dosage forms.
Cleaning Method Validation
Developing swab and rinse analytical methods with verified recovery factors to validate equipment cleaning limits on commercial manufacturing lines.
Analytical Transfer Protocols
Authoring analytical method transfer (AMT) protocols, comparative inter-laboratory testing, acceptance criteria review, and transfer reporting.
Out-of-Specification Investigations
Phase I laboratory investigations, re-test criteria, assignable root-cause identification, and scientifically justified corrective action reports.
Analytical Method Development, Validation and Technology Transfer
Modern regulatory guidelines advocate for an Analytical Target Profile (ATP) approach, treating analytical methods as dynamic systems that require qualification across their operational lifecycle. A method established during early exploratory trials must adapt as dosage strengths change or manufacturing operations scale up.
Chromatographic Scouting & Development
Screening stationary phases (C18, C8, PFP, HILIC), evaluating organic modifiers, buffer pH ranges, column temperature effects, and gradient slopes to achieve optimal critical pair resolution.
Forced Degradation (Stress Testing)
Subjecting the drug substance and formulation to acid, base, peroxide oxidation, thermal stress, and photolysis to demonstrate stability-indicating capability and mass balance.
Pre-Validation & Protocol Generation
Establishing method range, testing sample solution stability, verifying filter compatibility, and authoring formal validation protocols with predefined acceptance criteria.
Formal Method Validation (ICH Q2)
Executing validation experiments covering accuracy across 50%–150% ranges, repeat precision, intermediate analyst precision, linearity ($R^2 \ge 0.999$), and deliberate flow/temperature variations.
Laboratory Transfer & Verification
Executing co-validation or comparative testing between sending and receiving labs, ensuring identical chromatographic profiles across disparate instrumentation.
Impurity Profiling, Nitrosamines, and Extractables & Leachables (E&L)
Regulatory health authorities review impurity qualifications with heightened scrutiny. Unidentified peaks, potential genotoxic substances, and container-closure interactions represent primary causes for dossier deficiency letters and complete response letters (CRLs).
KMS Pharma applies sensitive hyphenated techniques (LC-MS/MS, GC-MS, ICP-MS) to quantify impurities at parts-per-million (ppm) and parts-per-billion (ppb) thresholds, ensuring alignment with ICH Q3A, Q3B, Q3C, and Q3D guidelines.
Degradation & Process Impurities
Isolating and profiling synthesis by-products, degradation intermediates, and excipient-derived adducts across stability storage.
ICH Q3D Elemental Analysis
Screening Class 1, 2A, 2B, and 3 toxic heavy metals using ICP-MS down to ultra-trace levels to establish product safety risk assessments.
Extractables & Leachables (E&L)
Controlled extraction studies and migration monitoring for elastomeric stoppers, plastic bottles, pre-filled syringes, and ophthalmic delivery devices.
Nitrosamine Risk & Testing
Validated trace-level quantitation of NDMA, NDEA, NDIPA, and NDSRIs (nitrosated drug substance-related impurities) via high-resolution LC-MS/MS.
Residual Solvents (ICH Q3C)
Headspace GC-MS determination of Class 1, 2, and 3 volatile organic solvents carried over from raw materials or manufacturing steps.
Forced Degradation Elucidation
Determining degradation kinetics under hydrolytic, photolytic, and oxidative conditions to guide antioxidant and buffer selection.
Specialised Analytical Testing: IVRT, IVPT, and Administration Studies
Complex drug formulations, modified-release systems, and topical pharmaceuticals require specialized testing models to demonstrate performance equivalency and bioequivalence (BE) waiver suitability.
In Vitro Release Testing (IVRT): Evaluating release rate kinetics for semi-solid creams, ointments, and topical gels using automated Franz diffusion cells in compliance with USP <1724> and FDA draft guidances.
In Vitro Permeation Testing (IVPT): Measuring transdermal flux, dermal accumulation, and skin permeation kinetics across synthetic or excised skin models to support topical generic bioequivalence.
Nasogastric (NG) Tube Recovery Studies: Assessing recovery, clumping, adsorption, and sedimentation when oral suspensions or crushed granules are administered through enteral tubes.
In Vitro Phosphate Binding Studies: Measuring langmuir binding constants and capacity at variable physiological pH levels for polymer and inorganic phosphate binder drugs.
Alcohol-Induced Dose Dumping (ADD): In vitro dissolution testing across 0%, 5%, 20%, and 40% ethanolic media to ensure modified-release integrity.
Pharmaceutical Stability Studies in Line with ICH Guidance
Stability testing evaluates the chemical, physical, and microbiological integrity of drug products over their intended commercial shelf life. For global filings, stability data must encompass multiple climatic zones—specifically Zone IVb (30°C / 75% RH) for hot and humid regions including India, Southeast Asia, and Latin America.
KMS Pharma maintains fully mapped, continuously monitored stability chambers with redundant backup power to prevent data loss or excursion events during multi-year testing regimes.
Stability Protocol Formulation
Establishing test intervals (0, 1, 2, 3, 6, 9, 12, 18, 24, 36 months), container-closure orientations (upright vs inverted), and parameter limits.
Climatic Storage Conditions
Long-term (25°C/60% RH or 30°C/65% RH), intermediate (30°C/65% RH), accelerated (40°C/75% RH), and refrigerated conditions (2°C–8°C).
Photostability Stress Testing
Exposing finished product and primary packaging to ICH Q1B light exposure limits (> 1.2 million lux hours and > 200 watt-hours/m² UV energy).
Trend Analysis & Shelf-Life Extrapolation
Tracking degradation slopes, dissolution profile shifts, and statistical shelf-life modeling to justify commercial expiration dating.
In Vitro Dissolution Testing & Drug Release Profiling
Dissolution testing serves as a critical in vitro indicator of in vivo drug performance and bioavailability. Developing discriminative dissolution media allows formulation scientists to detect subtle changes in manufacturing parameters before initiating clinical bioequivalence (BA/BE) studies.
Our laboratories feature USP Apparatus I (Basket), Apparatus II (Paddle), and Apparatus III (Reciprocating Cylinder) dissolution systems with automated sampling to characterize release profiles across physiological pH conditions (pH 1.2, 4.5, 6.8).
Discriminative Method Design
Designing dissolution methods that distinguish between sub-optimal and bioequivalent formulations through surfactant and agitation optimization.
f1 / f2 Mathematical Modeling
Statistical similarity ($f2 \ge 50$) and difference ($f1 \le 15$) factor calculations against innovator reference products for biowaiver justifications.
Intrinsic Dissolution Rates
Wood's apparatus testing to determine the pure solubility and dissolution rate of new chemical entities independent of surface area.
Micron & Sub-Micron Sizing
Laser diffraction particle size analysis from nanometer to millimeter ranges, ensuring uniform suspension behavior and compressibility.
Regulatory Analytical Documentation for Global CTD Submissions
Analytical data is only as good as its documentation trail. Regulatory assessors from the US FDA, EMA, MHRA, and CDSCO expect complete traceability, ALCOA+ data integrity compliance, and clear justifications for analytical specifications.
KMS Pharma authors technical documentation that integrates seamlessly into Module 3 of Common Technical Documents (CTD and eCTD), assisting sponsors through technical review queries and pre-approval inspections (PAI).
Module 3 CTD Authoring: Writing sections 3.2.S.4 (Control of Drug Substance) and 3.2.P.5 (Control of Drug Product), including analytical procedures, validation reports, and justification of specifications.
Quality by Design Integration (QbR): Documenting analytical target profiles, method risk assessments, and method control strategies in Question-based Review formats.
Regulatory Agency Query Resolution: Formulating scientific, data-backed responses to official deficiency letters and technical requests from health authorities.
Audit Trail & Data Integrity Compliance: Fully compliant chromatographic data systems (CDS) with electronic signatures, audit trail reviews, and multi-tiered access control under 21 CFR Part 11.
Advanced Analytical Instruments and Laboratory Equipment
Reliable analytical research requires high-precision instrumentation qualified under strict Installation, Operational, and Performance Qualification (IQ/OQ/PQ) standards.
LC-MS/MS Systems
Triple quadrupole mass spectrometers for trace-level nitrosamine, genotoxic impurity, and bioanalytical quantitation.
GC-MS with Headspace
Gas chromatographs equipped with automated headspace samplers for volatile organic solvent and residual solvent analysis.
ICP-MS
Inductively coupled plasma mass spectrometers for multi-element heavy metal quantification under ICH Q3D.
Shimadzu HPLC Systems
High-pressure gradient systems with UV, PDA, and RI detectors for assay, dissolution, and related substance profiling.
Dionex Ion Chromatography
Ion chromatography systems for quantification of counter-ions, inorganic salts, and organic acids.
UV-Vis Spectrophotometers
Double-beam spectrophotometers for routine dissolution measurements and qualitative identification assays.
Electrolab USP I, II & III
Automated dissolution test apparatus with auto-sampling manifolds and temperature-jacketed vessels.
Franz Diffusion Cell Apparatus
Multi-cell diffusion systems for transdermal permeation and semi-solid drug release studies.
Particle Size Analysers
Laser diffraction and dynamic light scattering equipment for micron and sub-micron particle size distribution.
Environmental Chambers
Continuous-monitoring stability and photostability chambers meeting all ICH climatic condition requirements.
Karl Fischer & Physical Testers
Volumetric and coulometric KF titrators, digital viscometers, density meters, and conductivity meters.
Why Global Pharma Chooses India for Analytical Development
India has established itself as an indispensable analytical testing hub for international pharmaceutical innovators and generic drug manufacturers. Outsourcing analytical chemistry to India provides critical operational advantages:
Skilled Analytical Chemists
Access to postgraduate chemists and chromatographers experienced with global pharmacopeias (USP, Ph. Eur., IP, BP).
Cost-Effective R&D Budgets
High-caliber method validation and multi-year stability storage at a competitive cost structure compared to US and EU CROs.
Fast Project Turnaround
Agile scheduling that prevents chromatographic bottlenecks and accelerates formulation screening cycles.
Direct CDMO Alignment
Seamless transfer between Indian analytical development labs and local GMP manufacturing facilities across major pharma belts.
How to Choose an Analytical Development Partner in India
Selecting an analytical testing laboratory requires looking past marketing claims to evaluate hands-on technical competence, data integrity governance, and regulatory audit history.
Regulatory Audit Track Record: Ensure the facility has a clear compliance record and understands current regulatory expectations regarding data integrity and audit trail reviews.
Instrument Redundancy: Verify that the laboratory maintains multiple chromatographic systems (HPLCs, GCs) to prevent project delays during routine instrument maintenance.
Deep Impurity Isolation Experience: Confirm that the team possesses direct experience elucidating unknown degradation peaks and quantifying trace mutagenic impurities.
Formal Method Transfer Support: Ensure the contract includes on-site or virtual support during technology transfer to your commercial manufacturing or QC release site.
Transparent Communication: Look for defined Service Level Agreements (SLAs), dedicated project managers, and routine technical milestone reviews.
Discuss Your Pharmaceutical Analytical Development Project
Planning chromatographic method development, ICH stability studies, nitrosamine risk assessments, or specialized in vitro release testing in India? Contact KMS Pharma's analytical scientific leads to discuss your molecule, analytical targets, and testing schedules.
Start a Conversation